BlackfinBio's Strategic Acquisition of Parkinson's Patent Portfolio from OXB to Combat Neurological Disorders BlackfinBio Ltd has announced its acquisition of Parkinson's patent portfolio from OXB, aiming to enhance its gene therapy program targeting dopamine deficiency diseases.

BlackfinBio's Strategic Acquisition of Parkinson's Patent Portfolio from OXB to Combat Neurological Disorders #United_Kingdom #Parkinson's #Sheffield #BlackfinBio #OXB